State of New Jersey Common Pension Fund D Has $48.29 Million Stake in Gilead Sciences, Inc. $GILD

State of New Jersey Common Pension Fund D boosted its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 3.9% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 435,008 shares of the biopharmaceutical company’s stock after buying an additional 16,160 shares during the quarter. State of New Jersey Common Pension Fund D’s holdings in Gilead Sciences were worth $48,286,000 as of its most recent SEC filing.

A number of other hedge funds also recently made changes to their positions in GILD. Norges Bank bought a new stake in Gilead Sciences in the second quarter valued at approximately $2,150,268,000. Ameriprise Financial Inc. boosted its stake in shares of Gilead Sciences by 397.6% in the 2nd quarter. Ameriprise Financial Inc. now owns 6,748,403 shares of the biopharmaceutical company’s stock valued at $748,147,000 after purchasing an additional 5,392,191 shares during the last quarter. Invesco Ltd. increased its position in shares of Gilead Sciences by 33.5% during the second quarter. Invesco Ltd. now owns 13,521,228 shares of the biopharmaceutical company’s stock worth $1,499,098,000 after buying an additional 3,394,330 shares during the period. Assenagon Asset Management S.A. raised its stake in Gilead Sciences by 164.4% during the third quarter. Assenagon Asset Management S.A. now owns 3,489,062 shares of the biopharmaceutical company’s stock worth $387,286,000 after buying an additional 2,169,266 shares during the last quarter. Finally, Vanguard Group Inc. lifted its holdings in Gilead Sciences by 1.6% in the second quarter. Vanguard Group Inc. now owns 119,364,226 shares of the biopharmaceutical company’s stock valued at $13,233,912,000 after buying an additional 1,893,401 shares during the period. 83.67% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on the company. Weiss Ratings reissued a “buy (b)” rating on shares of Gilead Sciences in a research report on Thursday, January 22nd. Scotiabank raised their price objective on shares of Gilead Sciences from $140.00 to $177.00 and gave the stock a “sector outperform” rating in a research report on Wednesday. Cantor Fitzgerald boosted their target price on shares of Gilead Sciences from $135.00 to $155.00 and gave the company an “overweight” rating in a research report on Wednesday. Bank of America set a $162.00 price target on shares of Gilead Sciences and gave the stock a “buy” rating in a report on Wednesday. Finally, Royal Bank Of Canada upped their price objective on shares of Gilead Sciences from $103.00 to $118.00 and gave the company a “sector perform” rating in a report on Wednesday. Twenty-three research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $152.50.

Insider Buying and Selling

In related news, insider Johanna Mercier sold 28,000 shares of the stock in a transaction on Monday, November 17th. The stock was sold at an average price of $125.86, for a total value of $3,524,080.00. Following the completion of the sale, the insider directly owned 107,193 shares of the company’s stock, valued at approximately $13,491,310.98. This represents a 20.71% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Daniel Patrick O’day sold 115,640 shares of Gilead Sciences stock in a transaction on Friday, January 23rd. The stock was sold at an average price of $135.00, for a total transaction of $15,611,400.00. Following the transaction, the chief executive officer directly owned 566,698 shares in the company, valued at $76,504,230. This represents a 16.95% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 319,391 shares of company stock worth $44,141,101 over the last three months. Company insiders own 0.27% of the company’s stock.

Gilead Sciences Stock Performance

Shares of GILD stock opened at $154.98 on Friday. The company has a current ratio of 1.68, a quick ratio of 1.31 and a debt-to-equity ratio of 1.03. The firm has a fifty day simple moving average of $130.27 and a two-hundred day simple moving average of $122.32. Gilead Sciences, Inc. has a 12 month low of $93.37 and a 12 month high of $157.29. The firm has a market capitalization of $192.28 billion, a PE ratio of 22.89, a price-to-earnings-growth ratio of 1.24 and a beta of 0.36.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Tuesday, February 10th. The biopharmaceutical company reported $1.86 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.83 by $0.03. Gilead Sciences had a net margin of 28.90% and a return on equity of 49.46%. The firm had revenue of $7.93 billion during the quarter, compared to analysts’ expectations of $7.68 billion. During the same period last year, the company earned $1.90 earnings per share. The business’s revenue was up 4.7% on a year-over-year basis. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. Analysts forecast that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, March 30th. Stockholders of record on Friday, March 13th will be paid a $0.82 dividend. This represents a $3.28 annualized dividend and a dividend yield of 2.1%. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.79. The ex-dividend date of this dividend is Friday, March 13th. Gilead Sciences’s dividend payout ratio (DPR) is currently 46.68%.

Key Gilead Sciences News

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Gilead reported better-than-expected Q4 results and raised FY26 guidance, driving optimism about near-term revenue and EPS trends. Gilead Sciences, Inc. (NASDAQ:GILD) Just Reported And Analysts Have Been Lifting Their Price Targets
• Positive Sentiment: Major analysts lifted price targets and/or maintained Buy/Outperform ratings after the results — Wolfe Research to $170 (outperform), Oppenheimer to $165 (outperform), TD Cowen to $160 (buy), Deutsche Bank to $155 (buy) — signaling analyst conviction and providing upward pressure on the stock. Wolfe Research price target raise
• Positive Sentiment: BofA raised its price target to $162 and reiterated a Buy, reflecting post‑earnings confidence in Gilead’s franchises. BofA raises PT
• Positive Sentiment: Additional buy ratings from large banks — J.P. Morgan and Scotiabank reiterated/issued Buy calls — adding to institutional endorsement after results. J.P. Morgan buy Scotiabank buy
• Positive Sentiment: Pipeline & product catalysts: Yescarta label expansion and continued HIV franchise momentum (Biktarvy, Descovy, Yeztugo) are being highlighted as durable growth drivers and part of the investment case. Yescarta label expansion & dividend growth
• Neutral Sentiment: Analyst commentary and research pieces (Zacks articles) are flagging Gilead as a momentum/value candidate and discussing whether the HIV portfolio can sustain growth — useful context but not immediate catalysts. Zacks momentum Zacks on HIV portfolio
• Neutral Sentiment: Short‑interest reports in the feed show zero shares / NaN changes and a 0.0 days-to-cover — likely a reporting/data artifact rather than a meaningful market signal. (No external link available in the entry.)

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.